These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6873318)

  • 1. Study on the presence of abnormal proteins in the serum of oral contraceptive users.
    Syner FN; Moghissi KS; Agronow SJ
    Fertil Steril; 1983 Aug; 40(2):202-9. PubMed ID: 6873318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated abnormal proteins in the serum of Nigerian pill users.
    Wright EA; Temple VJ; Kapu MM
    Acta Physiol Hung; 1990; 75(3):201-4. PubMed ID: 2392942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of the "Beaumont" protein in serum of oral contraceptive users.
    Collins DC; Bain RP; Coan P; Macpherson RF; Blumenstein B; Hall WD
    Fertil Steril; 1983 Oct; 40(4):490-6. PubMed ID: 6617910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Contraceptive hormones, vascular risk and abnormal precipitation of serum gamma-globulins (author's transl)].
    Beaumont V; Lemort N; Lorenzelli L; Mosser A; Beaumont JL
    Pathol Biol (Paris); 1978 Dec; 26(9-10):531-7. PubMed ID: 85291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of oral contraceptive progestins on serum copper concentration.
    Berg G; Kohlmeier L; Brenner H
    Eur J Clin Nutr; 1998 Oct; 52(10):711-5. PubMed ID: 9805216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoking and use of oral contraceptives: impact on thrombotic diseases.
    Lidegaard O
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the epidemiology of oral contraceptives and disease.
    Prentice RL; Thomas DB
    Adv Cancer Res; 1987; 49():285-401. PubMed ID: 3314396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Globulines anormalment precipitables (GAP) in Nigerian users of progestogen-only pill.
    Wright EA; Temple VJ; Kapu MM; Mwaigwe MM
    Int J Gynaecol Obstet; 1990 Feb; 31(2):163-5. PubMed ID: 1968864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives.
    Fruzzetti F; Ricci C; Fioretti P
    Contraception; 1994 Jun; 49(6):579-92. PubMed ID: 8070263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the oral contraceptive pill on protein S and antithrombin-III levels in Malaysian women.
    Wong KK; Ng SC; Koong PL
    Med Sci Res; 1992 Jun 16-30; 20(12):439-40. PubMed ID: 12288974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptive agents.
    Shearman RP
    Med J Aust; 1986 Feb; 144(4):201-5. PubMed ID: 3945219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of thromboxane A2 in increased whole blood platelet aggregation in oral contraceptive users.
    Norris LA; Devitt M; Bonnar J
    Thromb Res; 1996 Feb; 81(4):407-17. PubMed ID: 8907290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contraceptive choices in women with coagulation disorders.
    Comp PC; Zacur HA
    Am J Obstet Gynecol; 1993 Jun; 168(6 Pt 2):1990-3. PubMed ID: 8512043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemostatic changes and the oral contraceptive pill.
    Norris LA; Bonnar J
    Baillieres Clin Obstet Gynaecol; 1997 Sep; 11(3):545-64. PubMed ID: 9488791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study.
    Lidegaard O
    BMJ; 1993 Apr; 306(6883):956-63. PubMed ID: 8490470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.